SWME news
Dr. Gutman Presents in House O24 Study at AARP National Event for Swiss Medica's 024 U.S. Consumer Debut
Canadian Corporate News via COMTEX
Oct 18, 2004 9:21:11 AM
TORONTO, ONTARIO, Oct 18, 2004 (CCNMatthews via COMTEX) --
Swiss Medica's U.S. consumer debut for the Company's O24(TM) Essential Oil Pain Neutralizer, October 14-16, in Las Vegas at the AARP National Event was met with an enthusiastic response. Dr. E. Michael Gutman, a double board-certified neuropsychiatric pain management specialist based in Orlando (Florida), presented the findings of a recent in-house patient outcome study. Reportedly, more than 25,000 AARP members and guests attended the Las Vegas national event, which featured presidential candidate John Kerry and First Lady Laura Bush, as well as numerous celebrities.
Featured speaker, Dr. Gutman, announced to AARP members in a packed, standing-room-only, presentation area, "O24 should be an integral part of everyone's pain management strategy." Dr. Gutman announced in his clinic's study that O24(TM) reduced pain by 73 percent in patients and that 86 percent benefited by four or more hours of pain relief when using the O24(TM) Essential Oil Pain Neutralizer. In the study, O24(TM) was compared to Ben Gay(R), Bio Freeze(R), Tiger Balm(R), and other pain relief medications, including pain pills. O24(TM) was preferred by an overwhelming percentage of patients who unanimously announced that O24(TM) was better than other brands compared.
"We are astounded by the rapid and resounding acceptance of the O24(TM) pain relief product from our target audience of the fifty-plus age group," said Grant Johnson, Swiss Medica's President and Chief Operating Officer. "Our very high expectations going into the AARP National Event were quickly surpassed, as witnessed by the robust demand for the Company's product at our exhibit booth. That was reflected in very strong ongoing O24(TM) product sales, when at one point we were selling bottles at the rate of one every three minutes."
About Swiss Medica Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.024zone.com
Swiss Medica's flagship product, the 024(TM) Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The 024(TM) pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is available in the United States and elsewhere by visiting www.024zone.com, for ordering details and store locators.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
Investor Relations Contact: Current Capital John Robinson 1 877 859 5200 or Press Contact: Sky Wallen Blue Skye Inc. (813) 732-6869 blueskyeinc@yahoo.com www.blueskyeinc.com NEWS RELEASE TRANSMITTED BY CCNMatthews
News 
Market Data 
Discover 
AI
